Cannabis News

Psychedelics Show Promise As An ‘Entirely New Type Of Anti-Inflammatory Treatment,’ Research Suggests

Published

9 months ago

October 13, 2025

admin

“Evidence is growing in the key to managing inflammation of psychedelics, including a major driver of many chronic body diseases, depression, arthritis and heart conditions.”

Nicholas Barnes at the University of Birmingham, through dialogue

Once hippies and hallucination experiences are synonymously exploring psychedelic drugs today for their medical potential. The stigma of this era was eliminating drugs according to laws, however, moved with mental health treatments, scientists have returned to this discussed izer of medicine.

Psilocybin substances (found in magical mushrooms) and Ayahuasca are seriously taking scientists and doctors, they do not have caused perspectives, but if they have potential healing.

Initially, he focused on treating mental health conditions such as depression, which only helps the drugs prescribed today. But these studies have been expanded to internalize diseases driven by the inflammation, which can help reduce the immune system soothing.

Laboratory dishes and animal exams and animal exams, DMT, LSD can release inflammatory molecules called cytokines called cytokines. These protein molecules also rheumatoid arthritis, asthma as well as depression, in addition to increasing brain damage, after traumatic brain injury.

Advantage of steroids

But these drugs have a great advantage over the typical anti-infinite medications against steroids, because psychedelics work because it works without removing healthy immune function, which is the main problem with steroids.

Important, these lab findings are beginning to confirm in human studies. The evidence is growing the key to managing inflammation of psychedelics, including one of many chronic body diseases, including depression, arthritis and heart conditions.

Take the active ingredient in psilocybin, magic mushrooms. In a study with 60 healthy participants, only one dose was enough for two inflammatory molecule-tnf-alpha and IL-6-6-6 – next week.

However, not all studies show the same light results. Some people only had a few participants and others were complex because some participants had previous drug experience, which may affect results.

It is a great challenge to learn psychedelic in medicine research because it is very difficult to get real drugs and hide the placebo. When someone has a great psychedelic experience, it’s obvious that they didn’t take the sugar pill.

This challenges to interpret the results, especially aspects such as moods, which can significantly cause expectations. Changes in the body, too, can cause such inflammation, this placebo effect.

Meanwhile, the Amazonian Brew with the DMT psychedelic drug showed the promising results of people with hard depression and patients. In a study, those provided by Ayahuasca reduced the level of an inflammatory marker called CRP.

The higher the CRP drop, the greater the improvements in humor. This suggests that reducing inflammation can lead to improving mental health and conditions like depression and schizophrenia are related to inflammation of the body.

Scientists believe that psychedelic is especially true for 5-HT2A recipient, a part of the brain cells that usually responds to serotonin, called the “happy hormone”.

This recipient establishes a chain of chemical reactions within the cells. Here are the amazing parts: inflammatory effects against psychedelicism would not rely on the same processes that cause mind to change mind experiences, such as some calcium signals and other well-studied means. In fact, researchers believe that different mechanisms that are not understood can be involved, though yet invented.

In an analysis of the anxiety of asthma, there were two drugs with similar psychedelic effects, (R) -Do (R) -Dotfm, different results against anti-inflamity. The first drug was completely reversed swelling, and the other did nothing. This even more suggests that anti-inflammatory effects can be separated from psychedelic effects, opening the door to develop more safier medication.

The next generation of inflammatory anti-inflammatory pipi-psychedelic drug-psychedelic drugs come from I call. These are medications designed to imitate the therapeutic benefits of psychedelics, without causing hallucinations.

Several drugs have been identified, such as DLX-001 and DLX-159, Delix Therapeutics, developing the American Pharmaceutical Company. These experimental drugs show answers that represent antidepressive effects of “travel without affecting. Inflammation could be transformed into many conditions related to inflammation, without the reluctance of a regulatory complication or patient associated with psychedelic.

Although research in the early stages, evidence is being built in psychedelic or new drugs developed, can become a completely new type of inflammatory anti-inflammatory. People with long-term inflammatory diseases begin and use more stringent and innovative placebo-controlled designs, we can think of immersing the world in the world of psychedelism to be unexpected diseases.

The potential of the hallucinogenic effects flows treatment for many patients with the conditions that inflammation complies with the fundamental role.

This story first published the interview.

Photo elements courtesy CarlosemMaskypy and Apollo.

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

Cannabis News

cbdMD welcomes White House call for fair treatment of hemp-derived products

Published

15 hours ago

June 29, 2026

admin

cbdMD welcomes the Administration’s call for Congress to ensure fair treatment of hemp-derived products under federal law and calls for immediate action to revise hemp regulations to ensure fair treatment of hemp products under federal law.

In a letter to congressional leadership this week, the White House Office of Management and Budget identified hemp reform as a priority strongly supported by the Administration. The petition calls on Congress to ensure fair treatment of hemp-derived products by maintaining access to appropriate full-spectrum CBD products, and by maintaining Congress’ intent to reduce products that pose health risks. The administration also urged Congress to pass a responsible federal framework or at least extend the current implementation period to give lawmakers time to get policy right. The request builds on the president’s previous public statements urging lawmakers to protect access to full-spectrum CBD products that millions of Americans rely on.

“We are encouraged to see the administration so clearly championing the responsible, scientific hemp products that consumers depend on every day,” said Ronan Kennedy, CEO of cbdMD. “cbdMD has always believed that the future of this category is built on quality, transparency, and clear rules that separate them from bad actors. A federal framework that protects consumer access, promotes safety, and provides certainty to companies that provide certainty is what this industry and the people it serves deserve. We applaud the policymakers who are working to achieve this outcome.”

“We believe CbdMD is purpose-built for this next phase of the market,” added Kennedy. “Our focus remains on serving our customers with reliable and effective products, supporting responsible regulation and building long-term value for our shareholders as the category continues to evolve. Along the way, we will continue to evaluate the opportunities this evolving environment holds.”

For more information:
cbdMD
cbdmd.com/

Cannabis News

Applications For Missouri Marijuana Microbusiness Licenses Will Open Next Month

Published

15 hours ago

June 29, 2026

admin

“We have a lot of tutorials, and we also provide a step-by-step guide. Anyone could sit down and make the app. I don’t think it’s challenging.”

By Rebecca Rivas, Missouri Independent

Application window win one of Missouri’s 77 micro-business marijuana licenses through a lottery selection it will be open from July 13 to 27.

The selection lottery is scheduled for Sept. 9, and the Missouri Division of Cannabis Regulation expects to issue licenses in December, according to a press release issued Monday.

Microbusinesses are marijuana facility licenses issued to entities and individuals designed to allow marginalized or underrepresented people to legally participate in the marijuana market.

Lesley Turek, the division’s capital manager, has been traveling the state this month to educate people about the application process.

“I really feel that microenterprise graduates are, first and foremost, a community of people who help each other,” he said. “They’re the ones who are driving this program forward, so I’m looking forward to meeting new people and sharing as much as I can about the program. It’s a great program.”

Much of what is being worked on is the new rules that went into effect at the end of May…In 2024 the proposed cannabis regulators will remove a large number of licences Because of unconstitutional property deals.

The new rules, he said, allow regulators to conduct extensive scrutiny before licensing, rather than after. Furthermore, they give a more in-depth explanation of what it means to “have and operate the majority” of the License, which is a requirement in the Constitution.

Regulators are mandated to communicate directly with majority owners and require applicants to complete a compliance course before applying and after receiving a license.

The microbusiness program was passed by voters in the 2022 constitutional amendment to legalize recreational marijuana.

In Missouri, there are seven categories in which people can qualify for a micro-business license, ranging from lower income or living in an area considered poor, to past arrests or incarcerations related to marijuana offenses.

Applicants pay a $1,500 application fee if not selected. The Missouri Lottery will select 77 license applicants to open dispensaries or cultivation facilities. The goal is to fill the remaining gaps in the minimum 144 micro-business licenses mandated by the Constitution.

Turek believes the application is relatively simple and something people can complete on their own, unlike the much more complicated application for comprehensive licenses.

“We have a lot of tutorials, and we also offer a step-by-step guide,” he said. “Anyone can sit down and do the app. I don’t think it’s a challenge.”

The part that most people often don’t understand is everything that comes with owning a marijuana facility.

“It’s very expensive, it’s very regulated, and so it’s challenging,” he said. “I want to make sure people have a clear understanding beforehand so they can make a good decision whether they want to apply for this program.”

A big part of his presentation was that the majority of the licenses should be owned by and eligible people. They must have more than 50 percent of the authority to direct the decisions made with the license.

“It’s more than a percentage of ownership,” he said. “It’s really about being able to have that control over it.”

It also talks about the designated contact, and why in the new rule the regulators will require that the designated contact be the applicant or the eligible person with the majority of ownership.

The designated liaison role was conceived as a way to ensure clear communication between the state and licensees.

Instead, state regulators discovered it many named contacts have kept real applicants in the dark about business and licensing. Applicants are locked into agreements that limit their voting power and profits in the business.

That’s why the state now requires pre-application training, a three-video online course to ensure applicants understand “potentially predatory practices,” regulators said in response to public comments during the rulemaking process.

The press release It says those who need help with eligibility requirements or application forms can contact the facility’s application services (email protected).

Educational dissemination events for micro-enterprises

Personal forums:
June 22 – 6:00 pm to 8:00 pm – Kansas City

Webinars:
June 24 – from 11:00 a.m. to 1:00 p.m
June 29 – from 18:00 to 20:00

Registration is required for in-person and virtual sessions. Interested participants can register at Microenterprise education. Additional information on the microenterprise program is available here cannabis.mo.gov.

Those requiring assistance with eligibility requirements or application forms may contact Facilities Application Services at (email protected).

This story was first published by the Missouri Independent.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

RAND estimates Indiana adult-use cannabis could yield $180M in annual revenue

Published

2 days ago

June 28, 2026

admin

Two new RAND reports commissioned by the Richard M. Fairbanks Foundation outline the policy options and financial commitments facing Indiana as the state debates whether to change its cannabis laws amid restrictions across the country.

Reports show that 44% of Indiana residents live within 50 miles of a licensed dispensary in a neighboring state, and 96% live within 100 miles, as three of Indiana’s four states have legalized adult-use cannabis. At the same time, intoxicating hemp products containing the same psychoactive compound as marijuana are available at gas stations, convenience stores and grocery stores throughout Indiana with limited oversight.

Cannabis use in Indiana has doubled in the past decade, with a significant increase among adults 26 and older. RAND estimates that 1.3 million Hoosiers used cannabis in 2024 and spent $1.8 billion on marijuana products that year. Indiana recorded more than 13,000 cannabis-related arrests in 2024, with more than 90% for possession and more than 75% for non-cannabis related charges. The state spends $10 million to $20 million annually on cannabis law enforcement.

Rather than recommending a specific policy, the RAND reports outline four broad options: maintaining prohibition, reducing criminal penalties for possession, legalizing medical cannabis, or legalizing the adult recreational use market. Legalizing adult-use cannabis would generate about $180 million in annual state revenue, roughly 1 percent of the state’s general fund, well below some previous projections and less than half of the $385 million in combined cigarette and alcohol tax revenue Indiana will collect in 2025, according to the Indiana Department of Revenue.

Legalization would also entail significant upfront costs, and ongoing regulatory costs could reach the low tens of millions of dollars annually, outweighing the savings from reduced criminal justice spending. RAND identifies 14 policy considerations important to establishing legal markets, each with its own public health and state economic implications.